Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for clinical pharmacology studies
A method has been developed for the quantitation of
N′-(2-dimethylamino-benzoyl)urea (BPU) and its metabolites in human plasma and urine. BPU and metabolites were separated on a C18 column with acetonitrile–water mobile phase containing 0.1% formic acid using isocratic flow for 5
min. The analytes were monitored by tandem mass spectrometry. Calibration curves were generated over the range of 2.5–500
ng/mL for BPU, mmBPU, and aminoBPU in plasma; and 0.1–20, 0.1–20, 0.5–100, 10–2000, 1–200, and 3–600
ng/mL for BPU, mmBPU, aminoBPU, G280, G308, and G322 in urine, respectively. The method has been successfully applied to study the pharmacokinetics of BPU.